| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
Polo-like kinase1 (PLK1) belongs to the family of serine/threonine kinases and plays an important role in centrosome maturation, bipolar spindle formation, and cytokinesis during mitosis. We found in this study that PLK1 was aberrantly highly expressed in freshly isolated leukemia cells from individuals with acute myelogenous leukemia (AML, n=50) and acute lymphoblastic leukemia (ALL, n=15) compared to bone marrow mononuclear cells from healthy volunteers (n=13) (AML, p=0.016; ALL, p=0.008), as measured by real-time RT-PCR. Down-regulation of PLK1 by a small interfering RNA (siRNA) in NB4 AML cells inhibited their proliferation. GW843682X is a novel selective PLK1 inhibitor. The compound induced growth inhibition, caused accumulation of cells in the G2/M phase of the cell cycle and mediated apoptosis of human leukemia cells. Taken together, targeting PLK1 may be a promising treatment strategy for individuals with leukemia.
|
